Kainos Medicine, Inc. (KOSDAQ: 284620)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,965.00
+80.00 (2.06%)
Sep 11, 2024, 10:39 AM KST
1.67%
Market Cap 113.29B
Revenue (ttm) n/a
Net Income (ttm) 39.92M
Shares Out 28.18M
EPS (ttm) 6.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,236
Open 3,885.00
Previous Close 3,885.00
Day's Range 3,885.00 - 4,025.00
52-Week Range 2,275.00 - 7,100.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About Kainos Medicine

Kainos Medicine, Inc. researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer age... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 284620
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.